Staffing levels could thwart EMA's access to documents policy
This article was originally published in SRA
Staffing levels at the European Medicines Agency could prove a problem in light of the agency’s new policy on providing access to documents. Some delegates at yesterday's joint TOPRA/EMA meeting were concerned that the new policy could affect how the agency goes about its basic work, while others wondered whether the EMA would actually be able to fulfil its new obligations under the policy.
You may also be interested in...
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.